Glaxosmithkline Biologicals Sa

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Merck + Co., Inc.

Merck Sharp + Dohme Corp.

University of Copenhagen

Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.p.a.

Sabin Vaccine Institute

Instituto Di Recerche Di Biologia Molecolare P. Angeletti S.p.a.

Istituto Di Recerche Di Biologia Moleculare P. Angeletti S.p.a.

Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.p.a.

Oxford University Innovation Ltd

Riccardo Cortese

Alfredo Nicosia

Stefano Colloca

Virginia Ammendola

Alessandra Luzzago

Antonella Folgori

Alessandra Vitelli

Gary J Nabel

Gennaro Ciliberto

Cheng Cheng

Armin Lahm

Nancy J Sullivan

Paolo Monaci

Clement Asiedu

Maria Ambrosio

Andrew J Bett

David C Kaslow

John W Shiver

Emilio A Emini

Ralph Laufer

Annalise Di Marco

Isabelle Gloaguen

Franco Felici

Fabiana Grazioli

Adrian Vivian Hill

Rocco Savino

Arturo Reyes

Peter Johannes Holst

Domenico Lazzaro

Giacomo Paonessa

Anna De Martis

Anna Demartis

Anna Tramontano

Geraldine O'Hara

Patrizia Costa

Maria Rosaria Bassi

Anna Morena D'Alise

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).

Chimpanzee adenoviral vector-based filovirus vaccines

The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein, peptide or variant thereof, which induces an anti-pathogenic B cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture.

Expression systems

The present application provides inter alia a fusion protein comprising a polypeptide wherein the polypeptide consists of a fragment of invariant chain which is operably linked to an antigenic sequence and wherein the fragment of invariant chain consists of a portion of residues 17-97 of SEQ ID NO: 1, wherein the portion comprises at least 5 contiguous residues from residues 77-92 of SEQ ID NO: 1.

Fusion peptides with antigens linked to short fragments of invariant chain(CD74)

The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.

Poxviral vaccines

There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of:

Adenovirus polynucleotides and polypeptides

There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and(c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.

The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polynucleotides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.

Recombinant simian adenoviral vectors encoding a heterologous fiber protein and uses thereof

The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polypeptides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.

Chimpanzee clade E adenovirus nucleic acid-and amino acid-sequences, vectors containing same, and uses thereof

The invention provides recombinant adenoviral vectors which are capable of eliciting immunity against the pre-erythrocytic stage of the life cycle of the malaria parasite. In particular, the invention provides a recombinant, replication deficient simian adenoviral vector which encodes an antigen comprising the thrombospondin-related adhesion protein (TRAP), and also immunogenic compositions (e.g. vaccines) comprising the vector and methods of using such compositions.

Simian adenoviral vectors encoding malaria antigen

Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebola virus (EBOV) or Marburg virus (MARV).

Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein

The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.

Hepatitis C virus vaccine

Growing community of inventors

Rome, Italy

Riccardo Cortese